Wyss Diagnostics Accelerator seeks to fast-track disruptive
diagnostic technologies to meet unmet critical needs
Regensburg (Germany) and Boston (MA, USA), April 20th, 2023 — Lifespin GmbH, based in Regensburg (Germany), with offices in Boston, Massachusetts, announced today that it is one of 24 inaugural members of the Wyss Institute for Biologically Inspired Engineering at Harvard University’s Diagnostics Accelerator (Wyss DxA) Industrial Participant Program (IPP). The purpose of the Wyss DxA IPP is to serve as a collaboration hub for the industry-facing component of the Wyss Diagnostics Accelerator, which seeks to identify and fast-track new medical diagnostic technologies to address unmet or underserved healthcare needs.
Originally formed in 2021 as a pilot program, the IPP recently has transitioned from its pilot phase into an official program within the Harvard system, and consolidated its base of initial industrial partners, including Lifespin.
In a recent press release from the Wyss Institute, the Institute said that, “the IPP serves as a platform to explore collaborations across the diagnostic development pipeline, from early stage discovery through delivery of new diagnostics. Additionally, the IPP allows for member companies to connect with subject matter experts and key opinion leaders within the Harvard ecosystem, as well as through the Wyss DxA’s external network to key stakeholders, including investors, regulators, payors, and other important entities.”
Lifespin, an emerging medical start-up, is building a highly scalable, automated diagnostics technology platform that utilizes advanced digitized metabolomic data, proprietary software technology, and A.I., to identify unique biomarkers in a patient’s metabolism that may indicate both risk factors, and early stage disease states, with emphasis upon certain cancers, diabetes, obesity, and neurological disorders. Lifespin already has one of the largest and most comprehensive databases in the world of metabolic health profiles across healthy and diseased individuals covering multiple age and biological sex groups as well as specific diseases in neurology, oncology, and inflammation. Current developments in general health testing, oncology, and neurology yielding first regulated products in human diagnostics are expected in 2023.
Advancing the Science of the Metabolome
Use of the metabolome as a cost-effective and potentially more accurate diagnostics tool has long been of great interest to medical researchers. Identifying variations in the human metabolome that indicate the presence of disease before symptoms arise would open the door to a far more precise, and disruptive form of diagnostics that could eventually become the gold standard for numerous indications and new diagnostic products where none exist today including in precision drug monitoring for clinical, pharmaceutical and research settings; and precision nutrition for diabetes, obesity, dietary and lifestyle interventions.
“The framework of the Wyss DxA IPP is extremely well aligned with Lifespin’s mission to deliver new, disruptive innovation for high value health diagnostics problems,” said Dr. Ali Tinazli, CEO of Lifespin. “We are honored to be among a very select group of technology companies invited to participate in this important medical and scientific community, which will support our mission to advance the science of using digital metabolic profiles for the early detection of health conditions, staging of diseases, and monitoring treatment success.
The Wyss DxA IPP is co-led by Rushdy Ahmad, Ph.D., and David Walt, Ph.D. Walt is a Core Faculty member at the Wyss Institute, a Professor of Pathology at the Brigham and Women’s Hospital, and a scientific co-founder of several life science companies.
“The mission of the Wyss DxA is to get transformative diagnostic tests to market and reduce disease burden for patients with major unmet needs. We aim to compress timelines and measure impact on lives,” said Dr. Ahmad. “We are pleased to invite Lifespin to join the Industrial Partnership Program and support and foster meaningful partnerships within our stakeholder network.”
Safe Harbor Statement: This press release may contain forward-looking statements that involve risks, uncertainties, and assumptions. All statements other than statements of historical fact could be deemed forward-looking statements, including any projections of revenues, gross margins, earnings, or other financial items; statements regarding strategies or plans for future operations; statements concerning new features, enhancements, or upgrades to our existing applications or plans for future applications; statements relating to the expected performance or benefits of our offerings; statements about current or future economic conditions; and any other statements of expectation or belief. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements, and therefore you should not rely on any forward-looking statements that we may make.
Dr. Ali Tinazli, CEO, firstname.lastname@example.org , +1 310-467-1112 and +49-160-257-3458
David Paine, Public Relations, PaineLab, email@example.com, +1 949-233-0050
lifespin wird Teil eines exklusiven Diagnostiksverbundes in Harvard